PORTLAND, Oregon, November 15, 2016 /PRNewswire/ -- Global Renal Denervation Market projects the renal denervation market was worth $197 million in 2015 and is expected to reach $3,153 million by 2022 with a CAGR of 48.5%, according to new research published by Allied Market Research. Symplicity Renal Denervation System is estimated to continue generating highest revenue throughout the forecast period, owing to growing number of product approvals across the globe. Europe held the leading position in the global market in 2015, and is expected to maintain its lead in the future. (Logo: http://photos.prnewswire.com/prnh/20140911/647229 ) Increasing prevalence and incidence of hypertension and blood pressure, changing lifestyle of the people, improvement of healthcare infrastructure in developing countries, and cost effectiveness of the renal denervation procedure as compared to other multidrug treatment therapies propel the market growth. However, stringent approval process for renal denervation devices, and patient discomfort and pain that arises during the procedure hamper the market growth. Summary of the Renal Denervation Market Report can be accessed on the website at:https://www.alliedmarketresearch.com/renal-denervation-devices-market Vessix Renal Denervation System is projected to be the fastest growing segment, with a CAGR of 57.6% from 2016 to 2022, as this system can be used for arteries of variable diameter (has a balloon that can be expanded into variable sizes). In addition, it uses a full-color graphic user interface that increases the accuracy and operation of the device. Boston Scientific, manufacturer of Vessix Renal Denervation System, considers this market to be a potential growth opportunity for expanding its business. Symplicity is the major and most frequently used product of the renal denervation market."According to the CIRSE Member Survey (2013), Symplicity is used by approximately 78% of the European hospitals. This system is generally preferred as it delivers low level of RF energy and thus reduces thepotential risks associated with high levels of RF radiation on body tissues". Says Deepa Tatkare, Senior Analyst, Healthcare Research at AMR Radiofrequency was the most frequently used technology in the renal denervation market. In addition, it was the major segment in 2015 and is expected to lead throughout the forecast period. Ultrasound is projected to grow at the highest CAGR of 56.4%, as it overcomes the limitations of radiofrequency devices.